Thursday, November 14, 2013
Despite decades of research, respiratory syncytial virus
(RSV) remains a highly prevalent childhood pathogen without an approved
vaccine.1 There is a marketed prophylactic-Synagis
palivizumab-to prevent severe
disease caused by RSV in at-risk infants, but the passive immunization provided
by the antibody does not last from season to season, and its high cost
precludes its use in other patient populations. Now, a team from the NIH
has used structure-based design to generate RSV vaccines that showed strong
neutralizing activity in both mice and macaques.2
T. SciBX 6(44);
Published online Nov. 14, 2013
L.J. et al. Vaccine 31 Suppl. 2, B209-B215
J.S. et al. Science; published online Nov. 1, 2013;
Contact: Peter D. Kwong, National Institutes of Health, Bethesda, Md.
Contact: Barney S. Graham, same affiliation as above
B.S. Immunol. Rev. 239, 149-166 (2011)
R. et al. Lancet 380, 2095-2128 (2012)
K.A. et al. Proc. Natl. Acad. Sci. USA 108, 9619-9624 (2011)
J.S. et al. Science 340, 1113-1117 (2013)
COMPANIES AND INSTITUTIONS MENTIONED
AIMM Therapeutics B.V., Amsterdam, the
AstraZeneca plc (LSE:AZN; NYSE:AZN), London,
Emory University School of Medicine, Atlanta, Ga.
Geisel School of Medicine at Dartmouth, Hanover, N.H.
MedImmune LLC, Gaithersburg, Md.
National Institutes of Health, Bethesda, Md.
Novavax Inc. (NASDAQ:NVAX),